We describe an outbreak of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji. Molecular testing was conducted at the Microbiological Diagnostic Unit in Melbourne, Victoria, Australia. During January 2016–December 2018, a total of 96 confirmed or probable IMD cases were reported. Of case-patients, 61.5% (59/96) were male and 38.5% (37) female, 84.4% (81) were indigenous people of Fiji, and 70.8% (68) were children <15 years of age. Annual incidence increased from 1.8/100,000 population in 2016 to 5.2/100,000 population in 2018. Serogroup C multilocus serotype 4821 that is resistant to ciprofloxacin was prevalent (62.1%, 41/66). Public health measures, which included targeted mass vaccination with monovalent meningitis C vaccine, were effective in controlling the outbreak. We observed a rapid decline in meningitis C cases in subsequent years.

我们描述了由脑膜炎奈瑟菌血清型 C 引起的侵袭性脑膜炎球菌病 （IMD） 在斐济的暴发。我们使用标准调查表格创建了监测病例定义并收集了数据。在斐济进行细菌鉴定、抗菌药物敏感性检测和 PCR。分子检测在澳大利亚维多利亚州墨尔本的微生物诊断部门进行。2016 年 1 月至 2018 年 12 月期间，共报告了 96 例确诊或疑似 IMD 病例。在病例患者中，61.5% （59/96） 为男性，38.5% （37） 为女性，84.4% （81） 为斐济土著居民，70.8% （68） 为儿童 <15 岁。年发病率从 2016 年的 1.8/100,000 人增加到 2018 年的 5.2/100,000 人。对环丙沙星耐药的血清型 C 多位点血清型 4821 普遍存在 （62.1%，41/66）。公共卫生措施，包括有针对性的大规模接种 C 型脑膜炎疫苗，可有效控制疫情。我们观察到 C 型脑膜炎病例在随后几年迅速下降。